...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Optimization of a pharmacophore model for 5-HT4 agonists using CoMFA and receptor based alignment.
【24h】

Optimization of a pharmacophore model for 5-HT4 agonists using CoMFA and receptor based alignment.

机译:使用CoMFA和基于受体的比对优化5-HT4激动剂的药效团模型。

获取原文
获取原文并翻译 | 示例

摘要

Twenty two 5-HT4 agonists obtained from our laboratory and the recent literature were used to develop a CoMFA model to predict 5-HT4 agonist activity. Two models were produced and compared for predictivity, the first by alignments based on atom overlapping (model A) and the second by adding agonist binding site interacting points of the 5-HT4 receptor (model B). Comparison of the two models showed that the q2 value for model A was 0.564 vs. 0.582 for model B. Model B indicated that the predictive power model stems from far lower steric contributions, 0.270 compared to model A's 0.502. The dominant defining features were the electrostatic contributions for model B, 0.664 up from 0.477 in model A. The contributions from the LogP factor were minimal, 0.085 in both models. The synthesized compounds showed agonist activity at mumol level.
机译:从我们的实验室和最近的文献中获得的22种5-HT4激动剂被用于开发CoMFA模型来预测5-HT4激动剂的活性。产生了两个模型并比较了可预测性,第一个模型是基于原子重叠的比对(模型A),第二个是通过添加5-HT4受体的激动剂结合位点相互作用点(模型B)。两种模型的比较表明,模型A的q2值为0.564,而模型B的q2值为0.582。模型B表明,预测能力模型源于更低的空间贡献,与模型A的0.502相比,仅为0.270。主要的定义特征是模型B的静电贡献,从模型A的0.477上升到0.664。LogP因子的贡献极小,在两个模型中均为0.085。合成的化合物在摩尔水平上显示出激动剂活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号